Organ Preservation Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Market Trends and Insights

Rising Incidence of Multi-Organ Failure in Aging Populations

Life expectancy gains have enlarged the cohort older than 65, a group increasingly eligible for transplantation thanks to evidence showing comparable post-operative outcomes when frailty is managed. Chronic kidney disease, diabetes, and cardiovascular disorders all scale with age, lifting demand for reliable preservation that can cope with longer work-ups typical in geriatric cases. Hospitals therefore prefer solutions that protect organs during extended cold ischemia and offer functional assessment before implantation. Static cold storage remains widespread, yet machine perfusion’s ability to resuscitate marginal grafts is especially valuable when donor age rises. Transplant protocols now include geriatric assessment tools, reinforcing the need for flexible preservation windows that accommodate complex surgical schedules.

Technological Advancements in Preservation Techniques and Devices

Machine perfusion keeps donor organs at physiologic temperature, cutting primary graft dysfunction from 28% to 11% in recent heart studies. Donation-after-circulatory-death (DCD) hearts, once rarely used, are now feasible at scale under normothermic regional perfusion, with 606 U.S. cases recorded across 49 organ-procurement organizations^{[1]JAMA Network Open, “Normothermic Regional Perfusion Experience of Organ Procurement Organizations in the US,” jamanetwork.com}. Device makers integrate GPS tracking, pressure regulation, and temperature telemetry so that teams receive live alerts during transport. Cryopreservation research, such as X-Therma’s protein-mimetic ice blockers, aims to shift preservation from hours to weeks. These innovations collectively shorten allocation times, lower discard rates, and help surgeons expand donor criteria.

Increasing Government and NGO Initiatives for Organ Donation

The World Health Assembly adopted Resolution WHA77.4 that calls for every member state to meet transplant needs by 2035. In the United States, the HRSA OPTN Modernization Initiative modernizes allocation software and sets performance metrics for organ-procurement organizations. Medicare’s Increasing Organ Transplant Access Model mandates 2025 participation and ties hospital payments to higher kidney transplant volumes^{[2]Centers for Medicare & Medicaid Services, “Increasing Organ Transplant Access Model,” cms.gov}. China’s centralized allocation platform (COTRS) now covers every donation, boosting transparency and uptake across 35 transplant hubs. Month-long public campaigns such as National Donate Life Month enlisted 170 million registered U.S. donors in 2025.

Emergence of Reimbursement Codes for Ex-Vivo Perfusion

The CMS rule set published in 2024 establishes unique payment bundles for ex-vivo perfusion disposables and professional services, effective July 2025. Early adopters among U.S. transplant centers report quicker internal approvals for Organ Care System devices because cost recovery is now predictable. European health systems are piloting similar codes within Diagnosis-Related Group updates, spurring purchasing committees to reassess machine perfusion adoption timelines. Insurers increasingly recognize that a USD 30,000 perfusion kit can avert graft loss that would otherwise trigger a USD 400,000 re-transplant. As payer clarity expands, device manufacturers are scaling production lines to meet anticipated demand spikes, which could narrow price differentials with cold-storage supplies.

High Cost of Transplantation and Preservation Devices

Milliman estimates that total transplant episode expenses grow 5.2% annually for patients under 65, and 9.1% for older cohorts. The Organ Care System Heart requires hospital capital outlays above USD 250,000, and each disposable set adds roughly USD 40,000 per procedure. Preservation solutions also vary widely: University of Wisconsin solution costs USD 120 per liter versus USD 10 for Marshall’s formulation, pressuring cost-conscious hospitals despite equivalent graft survival scores in select cohorts. Developing regions therefore lag in NMP adoption, prolonging reliance on static cold storage. Budget limitations can also delay staff training and certification, which are prerequisite for advanced device use and data reporting.

Regulatory Uncertainty for Normothermic Perfusion

Normothermic devices traverse a patchwork of global frameworks. The FDA review spanned 5,518 days for the Organ Care System Heart, highlighting protracted evidence requirements. In Europe, Advanced Therapy Medicinal Product rules introduce added checkpoints for solutions infused with biologics, slowing multicountry trials. Asia-Pacific regulators still lack harmonized guidance for ex-vivo perfusion, causing device makers to file sequentially instead of concurrently. Without predictable timelines, venture investors price higher risk into funding terms, which can limit R&D budgets for next-generation platforms.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Organ Preservation Market Segment Analysis

Static Cold Storage retained 61.80% share of the organ preservation market in 2025 because of its simplicity, low cost, and decades-long validation in every transplant program. Even so, delayed graft function remains more frequent with extended criteria donors, prompting centers to trial perfusion add-ons that refresh metabolic substrates during transport. The organ preservation market size attributable to Static Cold Storage will grow modestly but cede share as perfusion adoption outpaces baseline growth.

Normothermic Machine Perfusion is projected to grow 10.31% annually through 2031 as multicenter data show 94% six-month heart graft survival versus 91% for ice storage. Hypothermic variants serve kidneys well by minimizing perfusate cost yet delivering measurable gains in delayed graft function, especially for extended criteria grafts. Regional perfusion in situ is rising too, with 606 U.S. DCD cases reported by 2024. The converging toolkit allows surgeons to sequence cold storage, hypothermic perfusion, and normothermic phases, tailoring methods to donor physiology and travel distance.

University of Wisconsin Solution accounted for 45.10% of the organ preservation market share in 2025. Its hyperosmolar, antioxidant-rich profile minimizes cellular edema and free-radical damage, establishing default use across kidneys, livers, and pancreas grafts. However, high potassium content and viscosity complicate pediatric use, inviting alternatives.

Custodiol HTK is expanding 9.18% CAGR on the appeal of low viscosity and cost parity for multi-organ procurement, with trials confirming similar liver graft survival to UW but simplified flushing protocols. Celsior targets cardiac grafts while Perfadex Plus remains standard for lungs, and new antioxidant-enhanced formulations under clinical review seek to further cut ischemia reperfusion injury. Specialized perfusates for machine perfusion, including proprietary oxygen carriers, represent an incremental revenue tier that supports premium pricing in the organ preservation market.

Preservation Solutions still delivered 49.30% share of the organ preservation market size in 2025 because every transplant, regardless of technology tier, requires a validated solution. That baseline demand keeps volume steady even as device categories accelerate. Manufacturers are reformulating solutions to lower potassium, add antioxidants, and extend shelf life, while digital supply-chain features maintain cold-chain integrity.

Transport Systems & Devices register the fastest 9.12% CAGR, led by Paragonix SherpaPak, LIVERguard, and BAROguard platforms that log GPS coordinates, internal temperature, and pressure in real time. A SherpaPak study covering 569 heart transplants showed a 54% mortality reduction at four years compared with ice storage. Device makers now bundle accessories and cloud analytics that forecast graft viability, turning hardware into recurring-income ecosystems. This software-embedded model attracts capital, as evidenced by Getinge’s USD 477 million buyout of Paragonix in 2024.

Kidneys made up 58.25% share of the organ preservation market size in 2025 because they constitute the largest transplant volume and enjoy robust reimbursement frameworks. Even so, 20% of deceased-donor kidneys are still discarded due to ischemic injury and logistics bottlenecks. Machine perfusion that permits viability scoring is helping centers accept marginal kidneys and slash discard rates, thereby protecting kidney segment volume in the face of rising comorbidities.

Lungs record the highest 10.48% CAGR thanks to breakthroughs like the HOPE technique that extends safe storage to 20 hours at 12 °C after normothermic perfusion. The continuous distribution allocation policy in the United States raised lung transplant counts 16% within a year, underscoring how preservation innovation amplifies allocation efficiency. Baroguard’s automated pressure control eliminates barotrauma risk during hypothermic transport, and early registry data indicate fewer primary graft dysfunction events relative to ice storage.

Transplant Centers controlled 42.35% revenue in 2025 because they purchase both solutions and capital equipment, dictate protocol standards, and receive direct reimbursement. Centers now benchmark graft-survival metrics to qualify for performance incentives under emerging value-based payment models.

Organ Procurement Organizations form the fastest-growing end user group at 11.10% CAGR. Normothermic regional perfusion allows OPO teams to recover three organs per DCD donor versus one when using static cold protocols. To scale that benefit, 95% of U.S. OPOs report the need for standardized training and device access. Hospitals and specialty clinics remain cost-sensitive but may accelerate adoption once payer frameworks stabilize and disposables pricing falls.

Geography Analysis

North America Organ Preservation Market

North America retained 36.55% share of the organ preservation market in 2025, underpinned by advanced infrastructure, the OPTN mandate to reach 60,000 annual transplants by 2026, and supportive reimbursement for perfusion. Widespread clinical trials, FDA device clearances, and robust donor-registration campaigns sustain first-mover advantage. Canada’s universal health coverage ensures demand continuity, while Mexico’s device imports rise as public hospitals expand transplant services.

Europe Organ Preservation Market

Europe exhibits steady but slower growth. Germany, France, Italy, Spain, and the United Kingdom lead adoption, yet cost-effectiveness assessments exert downward pressure on device prices. The European Society for Organ Transplantation’s roadmap for Advanced Therapy Medicinal Products spotlights regulatory caution that may defer rollouts for biologic-enhanced perfusates. Nonetheless, cross-border procurement networks in Eurotransplant and Scandiatransplant regions rely on high-performance transport systems to cover long-haul drives between donor and recipient hospitals.

APAC Organ Preservation Market

Asia-Pacific is the fastest-growing region, posting a 10.49% CAGR as transplant program capacity accelerates across China, India, and Japan. China’s COTRS platform legitimized voluntary donation and raised public trust, while new liver units achieve procurement rates comparable to mature Western centers. India’s rising medical tourism, coupled with domestic manufacturing incentives for perfusion devices, adds volume and price competition. Japan’s aging population creates high kidney and heart demand, and public insurers increasingly reimburse NMP in pilot projects.

Regulatory Landscape

Regulation for organ preservation products spans medical-device rules plus organ quality and safety requirements that govern procurement, transport, and traceability. In the United States, the FDA (CDRH) regulates perfusion and transport devices under risk-based pathways, including PMA for higher-risk systems such as OrganOx metra (PMA P200035) and De Novo classification for novel platforms (for example, DEN250009 in January 2026). FDA guidance addressing investigational device exemptions for hypothermic flushing, transport, and storage, and the use of animal studies to evaluate organ preservation devices, shapes trial design and evidence packages for market entry.

In Europe, market access is framed by EU Medical Device Regulation (EU) 2017/745 (MDR) for device safety and performance, alongside Directive 2010/53/EU on the quality and safety of organs for transplantation. Practice and quality benchmarks are reinforced by the Council of Europe/EDQM “Guide to the quality and safety of organs for transplantation” (9th edition, 2025), which is used as a reference for procurement, preservation, and transport processes, and sets compliance expectations for manufacturers supplying devices and solutions into multi-country transplant networks.

Market Opportunities and Future Outlook

The near-term whitespace centers on operationalizing dynamic preservation across more organs and more geographies, moving beyond static cold storage protocols that still dominate daily workflows. In the United Kingdom, NHS Blood and Transplant announced in November 2025 that normothermic regional perfusion (NRP) would be introduced as routine practice, supported by Department of Health and Social Care funding starting April 2026. That rollout pathway draws through demand for perfusion consumables, training, and retrieval-center capability upgrades. At the same time, payer and policy actions such as CMS payment bundles effective July 2025 for ex-vivo perfusion disposables and services continue to reduce internal approval friction at transplant centers by improving the predictability of cost recovery.

Clinical and translational evidence is also expanding room in underpenetrated segments such as pancreas, as well as in longer-distance, longer-duration logistics where viability assessment becomes more relevant. In July 2026, the University of Oxford reported a milestone in its Hypothermic Oxygenated Pancreas Perfusion (HOPP) study, with a study participant receiving a perfused human pancreas, signaling progress toward routine pancreas perfusion workflows that can complement or displace cold storage in selected cases. Alongside these milestones, industry efforts are shifting toward integrated ecosystems (device plus monitoring plus logistics) that support daytime surgery scheduling, “back-to-base” retrieval models, and standardized viability analytics, particularly for marginal donors where discard reduction improves throughput for OPOs and transplant centers.